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Abstract
Tetrodotoxin-resistant (TTX-R) sodium channels NaV1.8 and NaV1.9 in sensory neurons were known as key pain modulators.
Comparing with the widely reported NaV1.8, roles of NaV1.9 on inflammatory pain are poorly studied by antisense-induced
specific gene knockdown. Here, we used molecular, electrophysiological and behavioral methods to examine the effects of
antisense oligodeoxynucleotide (AS ODN) targeting NaV1.8 and NaV1.9 on inflammatory pain. Following complete Freund’s
adjuvant (CFA) inflammation treatment, NaV1.8 and NaV1.9 in rat dorsal root ganglion (DRG) up-regulated mRNA and
protein expressions and increased sodium current densities. Immunohistochemical data demonstrated that NaV1.8 mainly
localized in medium and small-sized DRG neurons, whereas NaV1.9 only expressed in small-sized DRG neurons. Intrathecal
(i.t.) delivery of AS ODN was used to down-regulate NaV1.8 or NaV1.9 expressions confirmed by immunohistochemistry and
western blot. Unexpectedly, behavioral tests showed that only NaV1.8 AS ODN, but not NaV1.9 AS ODN could reverse CFA-
induced heat and mechanical hypersensitivity. Our data indicated that TTX-R sodium channels NaV1.8 and NaV1.9 in primary
sensory neurons played distinct roles in CFA-induced inflammatory pain and suggested that antisense oligodeoxynucleo-
tide-mediated blocking of key pain modulator might point toward a potential treatment strategy against certain types of
inflammatory pain.
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Introduction
Chronic inflammatory pain is worldwide medical problem and
with only partial or low efficacy treatment options currently
available [1]. Investigations have shown that voltage-gated sodium
channels, especially tetrodotoxin-resistant (TTX-R) NaV1.8 and
NaV1.9, provided the potential therapeutic targets for inflamma-
tory pain [2–5]. At present, several problems have to overcome for
the successful application of TTX-R sodium channel blocking
drugs. On one hand, NaV1.8 or NaV1.9 selective blockers with
analgesic activity was hard to explore due to the high degree of
amino acid sequence homology among the multiple subtypes of
VGSCs [6]. Even the selective NaV1.8 blocker A-803467 showed
some suppressive effects on NaV1.2, NaV1.3, NaV1.5 and NaV1.7
at high concentration (over 1 mM) [7]. On the other hand, various
old (carbamazepine, phenytoin, lamotrigine and zonisamide) and
newly developed (oxcarbazepine, crobenetine) sodium channel
blockers also affect other pathological processes such as epilepsy,
spasticity, stoke or psychiatry [8,9]. Therefore, analgesic strategies
beyond direct blocking NaV1.8 or NaV1.9 at protein levels should
be considered for inflammatory pain modulation.
Facing to the complex mechanisms of inflammatory pain and
little relief of traditional pharmacotherapy, Glorioso et al recently
proposed that targeted delivery of specific pain gene therapy to
primary afferent neurons will provided novel approach alleviates
pain with less systemic side effects or the induction of tolerance
[10]. Antisense agents are valuable tools to inhibit the expression
of a target gene through mechanical disruption of the translation
process and RNase H-mediated RNA degradation [11,12]. In a
recent review, Kurreck compared three types of anti-mRNA
strategies including single stranded antisense oligonucleotides,
ribozyme-triggered RNA cleavage and small interfering RNA
molecules-induced RNA interference. The author pointed that
antisense oligonucleotides combined many desired properties such
as broad applicability, direct utilization of sequence information,
rapid development at low costs, high probability of success and
high specificity compared to alternative technologies for gene
functionalization and target validation [13]. It was shown that
NaV1.8 and NaV1.9 are preferentially expressed in a subset of
primary afferent sensory neurons in dorsal root ganglion (DRG)
but not in spinal cord [14,15]. The special anatomical sites of
DRGs lying along the vertebral column by the spine make it
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19865available to directly intrathecal delivery antisense agents and
minimize potential off-target adverse events [10]. Although the
applications of antisense oligodeoxynucleotides (AS ODNs)
targeting NaV1.8 in some inflammatory pain models have been
introduced [16–20], data on the effects of NaV1.9 AS ODN is very
limited.
The other reason triggering our present study came from a
recent negative report of NaV1.8 and NaV1.9 in pathological pain.
Leo et al demonstrated that the contributions of NaV1.8 and
NaV1.9 in knockout mice were quite limited and temporarily in
multiple models of acute nociception, peripheral inflammation and
neuropathic pain [21]. The presumed critical modulations of
NaV1.8 and NaV1.9 on pathological pain seemed to be challenged.
Considering the disadvantages of knockout mice in time-
consuming, clinical practice, labor intensity and potential
developmental compensatory mechanisms, it is necessary to
reevaluate the potential roles of NaV1.8 and NaV1.9 in the
process of inflammatory pain by antisense agents at different levels
including gene and protein expression, functions and behaviors.
Results
Expression profiles of NaV1.8 and NaV1.9 in DRG neurons
under the state of CFA-induced inflammatory pain
Following the establishment of CFA-induced inflammatory heat
and mechanical pain hypersensitivity (Figure S1), we examined
mRNA expressions of fiveisoforms of VGSCs (NaV1.1, NaV1.6,
NaV1.7, NaV1.8, NaV1.9) that mainly expressed in DRG neurons,
but not in spinal cord (Figure S2) [15,22]. DRG were harvested 1
day after CFA injection when the maximum effect on pain
hypersensitivity appeared [23,24]. As shown in Figure 1A and B,
there were no changes in the normalized mRNA levels of TTX-S
sodium channel NaV1.1 (from 10060.00% to 114.8066.70%,
n=3, p.0.05) and NaV1.7 (from 10060.00% to 98.9963.89%,
n=3, p.0.05), except for NaV1.6 (from 10060.00% to
139.6368.56%, n=3, p,0.05). The relative mRNA levels of
NaV1.8 and NaV1.9 were significantly increased after CFA
inflammation by 216.02625.52% and 187.86618.48%, respec-
tively (n=3, p,0.01).
We further compared NaV1.8 and NaV1.9 localizations by
double immunofluorescent labeling with NF-200, a marker of
large- and medium-sized neurons (Figure 1C and D). We found
that NaV1.8 mainly expressed in medium and small-sized DRG
neurons that rarely contain NF-200, whereas NaV1.9 just
appeared in small-sized DRG neurons that completely not co-
localized with NF-200 in naive rats (Figure 1C). After CFA
treatment, the percentages of Nav1.8- and Nav1.9-positive stains
to the total number of DRG neurons were increased from
50.4661.39 and 40.7864.80 to 77.4762.09 and 58.7362.15,
respectively (Figure 1D, n=8, p,0.001 or p,0.01). Western
blotting showed that the amount of NaV1.8 and NaV1.9 proteins
significantly increased after CFA treatment (Figure 1E). Densito-
metric analysis revealed that the average expressions of NaV1.8
and NaV1.9 proteins were increased by 84% and 52% (from
Figure 1. Expression profile of NaV1.8 and NaV1.9 at mRNA and protein levels following CFA treatment. (A) Representative RT-PCR
results of five isoforms of voltage-gated sodium channels. Amplicons of NaV1.1, NaV1.6, NaV1.7, NaV1.8, NaV1.9 and ß-actin were 540 bp, 509 bp,
441 bp, 515 bp, 572 bp and 229 bp, respectively. (B) Averaged fold changes of mRNA expression as normalized with naive control (n=3). (C) Double
immunofluorescent labeling of DRG neurons by anti-NaV1.8 (red) and anti-NF-200 (green) or anti-NaV1.9 (red) and anti-NF-200 (green) antibodies. (D)
The percentage of Nav1.8- and Nav1.9-positive profiles as a proportion of the total number of DRG neurons before and after CFA treatment (n=8). (E)
Western blotting examples of NaV1.8 and NaV1.9 in naive and CFA-treated DRG neurons. (F) Averaged protein expression of NaV1.8 and NaV1.9
between naive and CFA-treated DRGs (normalized with the internal control tubulin) (n=3 for each group). CFA, complete Freund’s adjuvant.
*p ,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0019865.g001
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p,0.01 or p,0.01) in CFA-treated rats (Figure 1F).
Enhancement of NaV1.8 and NaV1.9 sodium currents in
DRG neurons following CFA treatment
In DRG neurons, we identified three different components of
sodium currents, including TTX-S sodium current, NaV1.8-
mediated TTX-R current and NaV1.9-mediated persistent TTX-
R current (Figure 2). Electrical parameters for induction of the total
current (red) and the TTX-R sodium currents predominantly
mediated by NaV1.8 (green) and by NaV1.9 (black) were shown in
the left panel of Figure 2A. The TTX-S sodium current (blue) was
obtained by digital subtraction of the TTX-R sodium currents from
the total current (middle panel of Figure 2A). After CFA treatment,
the density of TTX-S sodium current not changed (Figure 2B, from
27.9863.13 to 27.3761.08 pA/pF, n=8, p.0.05). However, the
sodiumcurrentdensitiesmediated by NaV1.8and NaV1.9increased
55% (Figure 2C, from 251.6163.53 to 280.0665.20 pA/pF,
n=6, p,0.01) and 87% (Figure 2D, from 210.9160.66 to
220.4164.70 pA/pF, n=6–8, p,0.05), respectively.
Specific down-regulation of NaV1.8 and NaV1.9 protein
expression by i.t. AS ODN
Three days after intrathecal (i.t.) administration of FAM-labeled
ODNs, expressions of NaV1.8 and Nav1.9 were examined by
immunohistochemistry. There was no different in the number of
FAM-labeled DRG neurons in control and CFA. In control group,
the number of FAM-labeled cells in single DRG slice sample were
143.38610.01, 158.5065.92, 158.5166.14, 158.6268.89 in
NaV1.8 MM, NaV1.8 AS, NaV1.9 MM and NaV1.9 AS, respectively
(n=8, p.0.05). In CFA group, the number of FAM-labeled cells in
single DRG slice sample were 155.50611.84, 156.1366.70,
172.3866.08, 172.5067.10 in NaV1.8 MM, NaV1.8 AS, NaV1.9
MM and NaV1.9 AS, respectively (n=8, p.0.05). NaV1.8 or
NaV1.9 AS ODN treatment generated marked loss of NaV1.8- or
NaV1.9-positive DRG neurons in both naive and CFA-treated
groups (Figure 3A). Compared with MM control, AS ODNs
significantly decreased the percentage of TRITC-positive stains
(NaV1.8 or NaV1.9) in naive (NaV1.8 MM vs. NaV1.8 AS:
44.0161.88% vs. 26.0861.70%; NaV1.9 MM vs. NaV1.9 AS:
29.2962.05% vs. 17.5861.55%; n=8, p,0.001) and CFA-treated
rats (NaV1.8 MM vs. NaV1.8 AS: 72.6663.68% vs. 28.2962.61%;
NaV1.9 MM vs. NaV1.9AS: 50.5061.49%vs. 15.7960.90%; n=8,
p,0.001) (Figure 3B). Western blotting further showed that NaV1.8
and NaV1.9 AS ODNs significantly decreased protein expressions of
NaV1.8 and NaV1.9 in CFA treated rats (NaV1.8: from
150.37615.81% to 99.6565.04%; NaV1.9: from 130.7264.87%
to 96.8462.49%, n=5, p,0.01) (Figure 3C and D).
Inhibitions of NaV1.8 and NaV1.9 sodium currents by i.t.
AS ODN
Three days after i.t. administration of ODNs, the different
components of DRG neuronal sodium currents including NaV1.8-
Figure 2. Distinct changes in three components of sodium currents following CFA treatment. (A) Identification of different components
of sodium current through electrical stimulus protocols. The total current (red) was recorded with a 700 ms hyperpolarizing prepulse (from 280 mV
to 2120 mV) followed by a test pulse (40 ms, 210 mV). The TTX-R NaV1.8 sodium current (green) was recorded with a 700 ms depolarizing prepulse
(from 280 mV to 250 mV) followed by a test pulse (40 ms, 210 mV). The TTX-S sodium current (blue) was obtained by digital subtraction of the
TTX-R current from the total current. TTX-R NaV1.9 persistent sodium current (black) was recorded with a 700 ms hyperpolarizing prepulse (from
280 mV to 2100 mV) followed by a test pulse (40 ms, 240 mV). After CFA treatment, the density of TTX-S sodium current (B) was not changed
(n=6). Whereas the densities of TTX-R sodium currents of NaV1.8 (C) and NaV1.9 (D) were increased by 55% and 87% (n=6–8), respectively.
CFA, complete Freund’s adjuvant. * p,0.05; **p,0.01.
doi:10.1371/journal.pone.0019865.g002
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current and TTX-S current were tested in CFA treated groups
(Figure 4A). Compared with MM control, AS ODNs significantly
reduced the TTX-R sodium current density of NaV1.8 (from
261.7968.48 to 217.3063.80 pA/pF, n=6–7, p,0.01) and
NaV1.9 (from 229.7563.97 to 213.9362.84 pA/pF, n=6–7,
p,0.01). In contrast, AS ODNs had no effects on the TTX-S
sodium component (from 27.4661.55 to 29.9663.03 pA/pF,
n=6–7, p.0.05) (Figure 4B).
Reversal effect on CFA-induced pain hypersensitivity by
NaV1.8, but not NaV1.9, AS ODN
Compared with the baseline level (11.9160.16 s), s.c. injection
of CFA in MM ODN-treated rats caused significant reduction in
PWTL (5.7160.43 s, n=5, p,0.001) that could be reversed by
NaV1.8 AS ODN (12.0160.49 s, n=5, p,0.001), but not by
NaV1.9 AS ODN (4.6760.27 s, n=5, p.0.05) (Figure 5A).
Similarly, the significant reduction in PWMT of MM ODN-
treated rats caused by CFA treatment (from baseline value of
124.1364.40 mN to 50.9664.80 mN, n=5, p,0.001) could be
reversed by NaV1.8 AS ODN (113.6869.60 mN, n=5, p,0.001),
but not by NaV1.9 AS ODN (54.8867.33 mN, n=5, p.0.05)
(Figure 5B).
Discussion
In the present study, we got the following results. First, CFA
inflammation treatment caused increased expressions of NaV1.8
and NaV1.9 in primary sensory DRG neurons. Functional analysis
on the different components of voltage-gated sodium currents
[25,26] demonstrated that CFA treatment significantly increased
the sodium current densities of NaV1.8 and NaV1.9, but had no
effects on TTX-S sodium currents. Second, intrathecal adminis-
tration of NaV1.8 and NaV1.9 AS ODN significantly decreased
CFA-induced proteins up-regulation and functional enhancement
of TTX-R sodium channels. Third, behavioral tests showed that
NaV1.8, but not NaV1.9, AS ODN could reverse CFA-induced
Figure 3. Down-regulation of NaV1.8 and NaV1.9 expressions in rat DRG neurons by antisense oligodeoxynucleotides (AS ODNs).
(A) Examples of double immunofluorescent micrographs of DRG neurons from naive and CFA inflammation. FAM-labeled ODNs (green) were
observed primarily in the cytoplasm in nearly all cell bodies of DRG neurons 3 days after i.t. administration of ODNs. (B) The percentage of TRITC-
positive stains (NaV1.8 or NaV1.9) to the total number of FAM-labeled DRG neurons was significantly decreased by AS ODN in both naive and CFA-
treated rats (n=8). (C) Representative western blotting of NaV1.8 and NaV1.9 in DRG neurons from naive and CFA-inflamed rats following i.t.
administration of ODNs. (D) Averaged percent changes in the amount of NaV1.8 or NaV1.9 protein level in DRGs of naive and CFA-treated rats (n=5).
CFA, complete Freund’s adjuvant. AS, antisense. MM, mismatch. ODN, oligodeoxynucleotide. FAM, carboxyfluorescein. TRITC, tetramethylrhodamine-
5-(and-6)-isothiocyanate. **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0019865.g003
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key pain modulators NaV1.8 and NaV1.9 played distinct
regulations on the processing of CFA-induced inflammatory pain
and that antisense oligodeoxynucleotide-mediated blocking of
NaV1.8 over-expression might point toward a potential treatment
strategy against certain types of pathological pain.
It should be noted that inflammatory pain is complexed with
multiple modulators including neurotransmitters, receptors and
voltage-gated ion channels [27] and diverse pain behaviors
including spinal withdrawal reflexes, spino-bulbospinal jumping
or abdominal stretching reflexes and simple vocalization, scratch-
ing, biting, licking and guarding behaviors. These pain modulators
and behaviors can be evaluated through a variety of pain models
(such as formalin, CFA, carrageenan, urate crystals, zymosan,
bradykinin, pro-inflammatory cytokines, neurotrophin, prosta-
glandins, serotonin and substance P in differential degrees [28]. In
present study, we reported that NaV1.8 antisense generated
inhibitory effects on CFA-induced inflammatory pain. However,
NaV1.8 antisense-mediated inhibitory effects might not generate
same biological regulations in all other inflammatory pain models.
It was reported that NaV1.8 antisense had no effects on
carrageenan-induced inflammatory pain behaviors [20]. Our
unpublished data also indicated that antisense targeting NaV1.9,
but not NaV1.8 could inhibit pain behaviors induced by melittin,
another inflammatory pain model well established in our lab [29].
We think that NaV1.8 and NaV1.9 exert distinct regulations on
inflammatory pain and even the same pain modulator might play
different roles in a variety of pain conditions.
Nociceptive DRG neurons expressed TTX-R sodium channels
NaV1.8 (SNS/PN3) [14] and NaV1.9 (NaN/SNS2) [15]. Double
labeling studies demonstrated that NaV1.9 mainly expressed in
non-peptidergic isolectin B4 (IB4)-positive DRG neurons and
NaV1.8 showed in both IB4-positive and peptidergic IB4-negative
and neurons [30]. NaV1.8 and NaV1.9 have distinct intrinsic ion
channel properties related to neuronal functions: (1) NaV1.8 and
NaV1.9 perform different electrogenic properties. NaV1.8 has high
activation threshold and slow inactivation kinetics and the channel
opening leads directly to the generation of action potentials [31],
Figure 4. Effects of ODNs on sodium currents in DRGs from CFA-treated rats. (A) Example current traces represent TTX-R sodium channels
NaV1.8 and NaV1.9 and TTX-S sodium channels in DRG neurons 3 days after i.t. administration of MM ODN, NaV1.8 AS ODN or NaV1.9 AS ODN in CFA-
inflamed rats. (B) Averaged sodium current density of NaV1.8, NaV1.9, and TTX-S sodium currents (n=6–7) recorded in DRG neurons of CFA-inflamed
rats 3 days after i.t. administration of MM ODN, NaV1.8 AS ODN or NaV1.9 AS ODN. CFA, complete Freund’s adjuvant. AS, antisense. MM, mismatch.
ODN, oligodeoxynucleotide. **p,0.01.
doi:10.1371/journal.pone.0019865.g004
Figure 5. Effects of NaV1.8 and NaV1.9 ODNs on CFA-induced pain hypersensitivity. MM or AS ODNs (45 mg/5 ml) were i.t. administered
twice daily for three consecutive days. CFA was s.c. injected on the morning of day 3 and pain hypersensitivity behaviors were tested on the morning
of day 4 afterward while receiving ONDs administration. The results showed that NaV1.8 and NaV1.9 AS ODNs had different effects on CFA-induced
heat (A) and mechanical (B) hypersensitivity. CFA, complete Freund’s adjuvant. PWTL, paw withdrawal thermal latency. PWMT, paw withdrawal
mechanical threshold. AS, antisense. MM, mismatch. ODN, oligodeoxynucleotide. **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0019865.g005
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and generates a prominent persistent sodium current at sub-
threshold voltages that may regulate subthreshold excitability in
small DRG neurons [32,33]. (2) NaV1.8 and NaV1.9 contribute
differently to AP generation. NaV1.8 can modulate AP threshold
and overshoot [22] and is responsible for the majority (80–90%) of
action potential electrogenesis in nociceptive DRG neurons [34].
However, NaV1.9 seems to be not directly involved in the
generation of action potentials [35] since neurons from NaV1.9
gene knockout mice can exhibit normal action potential
characteristics in RMP, threshold, amplitude and duration as
shown in wild type mice [36]. These different electrophysiological
properties between NaV1.8 and NaV1.9 might affect the
contributions of TTX-R sodium channels in the process of
pathological pain.
To our knowledge, the contributions of NaV1.9 in pain
modulation were poorly understood although some researchers
proposed that NaV1.9 should play specialized roles in pain
pathways due to its restricted distribution within small DRG
neurons [15,37–39]. In the current study, we found that although
the gene and protein level of NaV1.9 were significantly increased
and NaV1.9-mediated current density was greatly enhanced by
CFA treatment, down-regulation of NaV1.9 by specific antisense
failed to affect CFA-induced pain hypersensitivity. The less
contribution of NaV1.9 seemed to be consistent with two previous
reports. One showed that NaV1.9 knockdown had no effect on
nerve injury-induced behavioral responses [20], the other showed
that NaV1.9 knockout failed to change the neuronal hyperexcit-
ability induced by nippostrongylus brasiliensis chronic inflamma-
tion [40]. However, another study disrupting NaV1.9 coding
sequence with IRES-LacZ-neo in mice indicated that the
expression of NaV1.9 contributed to the persistent heat hypersen-
sitivity after CFA or carrageenan treatment [36]. We noted that, in
that paper, CFA-induced thermal latency was not changed in
NaV1.9 null mice at two time points (6 and 24 h after CFA
injection) when the most significant heat hyperalgesic responses
appeared in wild type mice. Also, there was no difference in
carrageenan-induced thermal latencies between NaV1.9 null and
wild type mice when heat hyperalgesia was demonstrated at three
time points (1, 2 and 3 h after carrageenan injection). Following
that report, another gene manipulation experiment by deleting
exons 4, 5, and 6 of NaV1.9 showed that CFA-induced
inflammatory heat hypersensitivity was diminished in NaV1.9
2/2
mice during all the detected time points from 1 to 7 d after
inflammation treatment [41]. At present, we don’t know why
NaV1.9 upregulation had nearly no effects on CFA-induced
inflammatory pain behaviors. We noted that NaV1.9 strictly
distributed in small-sized DRG neurons and completely not co-
localized with large- and medium-sized neuronal marker NF-200.
The limited distribution of NaV1.9 in primary sensory neurons
might be of no consequence in determining the overall pain level
following certain types of inflammation treatment. In addition,
different experimental approaches and pain models evaluating
NaV1.9 should be considered. It was shown that NaV1.9 knockout
just played inhibitory regulations on imflammation-induced
visceral hyperalgesia [42], rather than somatic inflammation and
neuropathic pain [21]. Nevertheless, conflicting evidences on the
roles of NaV1.9 are intriguing for further investigations.
Recently, the potential roles of TTX-S sodium channel NaV1.6
were introduced in neuropathic pain models. It was shown that
NaV1.6 protein significantly increased proximal to the lesion site
after infraorbital nerve injury [43] and that NaV1.6 gene
transcription up-regulated in non-injured L4 DRG neurons
following tightly ligation of L5 spinal nerve [44]. In present study,
we found that mRNA expression of NaV1.6 increased 40%
following CFA inflammation treatment. It remains interesting to
study whether NaV1.6 in DRG participates in inflammatory pain
in future. However, providing NaV1.6 as the potential analgesic
target was quite limited because this sodium channel isoform
widely located at nodes of Ranvier of both sensory and motor
axons in the peripheral nervous system and at nodes in the central
nervous system [45].
As an implantable therapy, intrathecal infusion in the treatment
of chronic intractable pain might provide positive long-term
outcomes and act as an advanced-stage therapy for refractory pain
[46]. In present study, mainly by intrathecal antisense adminis-
tration protocol, we supported the major contributions of NaV1.8
in primary sensory neurons for CFA-induced inflammatory pain
behaviors. There is still a long way, however, to succeed in clinical
applications since many other factors (such as patient selection,
delivery system, potential complication and safety qualification)
should be carefully and thoroughly evaluated. Nevertheless,
further understanding the pathway, safety, and efficacy of
antisense-mediated knockdown of specific pain modulator might




The experiments were performed on male Sprague-Dawley
albino rats (purchased from Laboratory Animal Center of the
Fourth Military Medical University, FMMU, China) weighing 80–
120 g (age .3 postnatal weeks). The animals had access to water
and food ad libitum, and maintained at room temperature (22–
26uC) with a light/dark cycle of 12 h. The experimental
procedures were approved by the Institutional Animal Care and
Use Committee at FMMU (approval number: SCXK2007-007).
The number of animals used and their sufferings were minimized.
Behavioral test
CFA (100 ml, 1:1 dissolved in 0.9% sterile saline) was injected
into the plantar surface of rat hindpaws to induce inflammatory
pain [47] and maximum effect on pain hypersensitivity appeared
24 h after CFA injection [23,24]. All behavioral tests were
performed by observers blinded to the experimental conditions
as previously reported [48,49]. To assess heat hypersensitivity, rats
were placed in a plastic chamber on the surface of a 2 mm thick
glass plate and the sensitivity to heat stimuli was detected by RTY-
3 radiant heat stimulator (Xi’an Bobang Technologies of Chemical
Industry Co. Ltd., China). The heat stimuli were applied to both
the injection site and the corresponding area of the contralateral
paw, and the latency was determined as the duration from the
beginning of heat stimuli to the occurrence of a marked
withdrawal reflex. Five stimuli were repeated for each site and
the latter three or four values were averaged as mean paw
withdrawal thermal latency (PWTL, s). For evaluation of
mechanical hypersensitivity, mechanical stimuli were applied by
using ascending graded individual von Frey monofilaments with
different bending forces (mN): 4.9, 9.8, 19.6, 39.2, 58.8, 78.4, 98.0,
117.6, 137.2, 156.8, 176.4, 196.0, 245.0, 343.0, 441.0, and 588.0.
A bending force being able to evoke 50% occurrence of paw
withdrawal reflex was expressed as the paw withdrawal mechan-
ical threshold (PWMT, mN).
Cell preparation
DRGs were prepared to study 1 day after CFA injection when
the maximum effect on pain hypersensitivity appeared [23,24].
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and ganglion was removed and chopped in half. Pieces of ganglia
(L4-6) were incubated lasting for 40 min at 37uC with DMEM
solution (Sigma-Aldrich, Saint Louis, MO, USA) containing
1 mg/ml collagenase (type I A, Sigma) and 0.4 mg/ml trypsin
(type I, Sigma). After three washes in standard external solution (in
mM): 150 NaCl, 5 KCl, 1 MgCl2, 2.5 CaCl2, 10 HEPES and 10
glucose, individual cells were dispersed by trituration with a fire-
polished Pasteur pipette and plated on glass cover slips. Cells were
incubated in standard external solution at 33uC for 0.5–1 h.
Experiments were carried out within 8 h and these cells retained a
healthy appearance and had negative resting potentials and
overshooting action potentials. We mainly recorded neurons
ranging from 20–40 mm in diameter as directly observed through
IX71 microscope (Olympus, Japan).
Whole cell patch-clamp electrophysiology
All recordings were made with EPC10 amplifier and Pulse
software (HEKA Elektronik, Germany). The data were analyzed
by Igor software (Configuration Metrics, Inc. Oregon, USA).
Patch electrodes fabricated with P-97 Puller (Narishige, Japan) had
resistances of 3–5 MV. After GV-seal whole-cell formed at room
temperature (20–22uC) under voltage-clamp holding at 270 mV,
capacitance transient was cancelled, serious resistance was
compensated (.80%) and leak current was subtracted digitally.
Initial input resistances were within the range of 800 MV to
1.5 GV. The liquid junction potential between the pipette solution
and the bath solution (approximately 210 mV) was corrected.
The membrane capacitance was read from the amplifier to
determine the size of cells and to calculate the current density.
For voltage clamp recording of sodium current, electrodes were
filled with (in mM): 100 CsCl, 40 tetraethylammonium-Cl, 5
NaCl, 1 CaCl2, 2 MgCl2, 11 EGTA, 10 HEPES, 2 Mg-ATP
(pH 7.2, osmolarity 310 mOsm) [19]. Bath solution used to record
whole cell sodium currents contained (in mM): 35 NaCl, 30
tetraethylammonium-Cl, 65 choline-Cl, 0.01 CaCl2, 5 MgCl2,1 0
HEPES, 10 glucose (pH 7.4, osmolarity 320 mOsm). According to
previous studies [25,26], different electrical stimulus protocols
were used to clarify the three different components of sodium
currents. The total current was recorded with a 700 ms prepulse to
2120 mV followed by a test pulse (40 ms, 210 mV). The TTX-R
sodium current (predominantly mediated by NaV1.8) was recorded
with a 700 ms prepulse to 250 mV followed by a test pulse
(40 ms, 210 mV). The TTX-S sodium current was obtained by
digital subtraction of the TTX-R sodium current from the total
current. Pervious studies showed that the maximum current of
NaV1.9 was generated with depolarizations to about 230 mV
[35]. However, the same depolarizations also could activate
NaV1.8-mediated slow-inactivating current if one DRG neuron
expressed both NaV1.8 and NaV1.9 [50]. To minimize the
contamination of NaV1.8, we used the following protocol to record
persistent NaV1.9 current: 700 ms prepulse to 2100 mV followed
by a test pulse (40 ms, 240 mV) (also see Figure 2a).
RT-PCR
Total RNA was isolated from L4-L6 DRGs with Total RNA
Extraction Kit (Omega Bio-Tek, Norcross, GA, USA) following
the manufacturer’s instructions. Total RNA (1 mg) was reverse
transcribed with BioRT Two Step RT-PCR Kit (BioER,
Hangzhou, China) in a 20 ml reaction mixture. Reverse transcrip-
tion was carried out at 37uC for 10 min, followed by 45uC for
45 min and 95uC for 5 min. Primer sequences specific for rat
NaV1.1, NaV1.6, NaV1.7, NaV1.8, NaV1.9 and ß-actin were based
on previously reported (Table S1) [51]. PCR was performed in a
25 ml system containing 2 ml templates, 12.5 ml AmpliTaq (PCR
Kit, Amresco, USA) and 0.4 mM primers for each gene on a DNA
Thermal Cycler. The PCR conditions were 30 cycles of 94uC for
30 s, 57uC for 30 s, and 72uC for 60 s. PCR products (5 ml) was
subjected to electrophoresis on 1.0% agarose gels and stained by
ethidium bromide. The stained gels were visualized under UV
illumination with FluorChem FC2 (Alpha Innotech Corp., San
Leandro, CA, USA) and band intensities were analyzed with
AlphaView v.1.3.0 (Alpha Innotech Corp). Three independent
PCR reactions were performed to determine the average mRNA
change.
Double immunofluorescent histochemistry
DRGs (L4-6) were fixed with 4% paraformaldehyde in 10 mM
phosphate buffer (PB) overnight at 4uC, cytoprotected in 10 mM
PB containing 30% sucrose. Transverse frozen sections (20 mm
thick) were cut on CM1900 freezing microtome (Leica, Germany),
incubated for 4 h in 0.05% Triton X-100 and 10% goat serum in
phosphate buffered saline (PBS) at room temperature, followed by
incubation with primary antibodies at 4uC overnight with
agitation. After three washes with PBS, the sections were
incubated with secondary antibodies for 2–3 h at room temper-
ature. The primary antibodies were mouse anti-Neurofilament
200 monoclonal antibody (NF-200, 1:200, Sigma, USA), rabbit
anti-rat Nav1.8 and Nav1.9 antibodies (1:200, Alomone, Israel).
Secondary antibodies were FITC-conjugated bovine anti-mouse
IgG (1:200, Santa Cruz Biotechnology, Inc., CA, USA) and
TRITC-conjugated goat anti-rabbit IgG (1:400, Santa Cruz).
Photomicrographic images were obtained under a laser scan
confocal fluorescent microscope (Olympus FV1000, Japan). Cells
were counted by Image-Pro Plus digitizing software (Olympus,
Japan) based on the optical density and the size of the object and
only that were clearly positive under the microscope were
analyzed.
Western blotting
NaV1.8 and NaV1.9 proteins in rat L4-6 DRGs were examined
as previously described [52]. Total proteins from rat L4-6 DRGs
were extracted by homogenization in ice-cold RIPA lysis buffer
(Applygen Technologies Inc., China) containing 50 mM Tris
(pH 7.4), 150 mM NaCl, 1% NP-40 and 0.1% sodium dodecyl
sulphate (SDS). Protein concentrations were determined by a
BCA
TM protein assay kit (Thermo Scientific, Rockford, IL, USA.).
Samples were heated for 10 min at 95uC with SDS-PAGE sample
buffer and same amounts of proteins (30 mg) were separated by 6%
SDS-PAGE separation gels, and were subsequently transblotted
onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA).
We used rabbit anti-rat NaV1.8 and NaV1.9 monoclonal
antibodies (1:200, Alomone) as primary antibodies and horserad-
ish peroxidase (HRP)-conjugated goat anti-rabbit IgG as second-
ary antibody (1:10000, Bio-Rad). Mouse anti-rat monoclonal ß-
tubulin antibody (1:10000, Sigma-Aldrich) was used as internal
control. The membranes were developed with ChemiGlow West
chemiluminescent substrate kit (Alpha Innotech Corp) and the
signals were captured with FluorChem FC2 (Alpha Innotech
Corp.). Scanned images were analyzed by Quantity One 1-D
Analysis Software (Bio-Rad).
Antisense oligodeoxynucleotides delivery
Antisense oligodeoxynucleotides (AS ODNs) specific targeting
NaV1.8 and NaV1.9 were previously reported [20] and the
sequences were 59-TCCTCTGTGCTTGGTTCTGGCCT-39
and 59- GCCTTGTCTTTGGACTTCTTC-39, respectively.
The mismatch oligodeoxynucleotide (MM ODN) sequence was
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labeling of ODNs were carried out by conjugation of carboxy-
fluorescein (FAM) to the 59 end of the ODNs, and synthesized as
phosphodiester ODNs using standard O-cyanoethylphosphorami-
dite chemistry (Shanghai Sanggon Biological Engineering Tech-
nology Services Co., Ltd, China). Intrathecal (i.t.) delivery method
was previously described [48] and ODNs (45 mg/5 ml, dissolved in
nuclease-free ultrapure water) were i.t. administered twice daily for
three consecutive days.
Statiscal analysis
All data were expressed as means 6 standard error (SEM).
Statistical comparisons were performed using one-way ANOVA
followed by Fisher’s PLSD test. Statitical significance was
indicated by a P value,0.05.
Supporting Information
Figure S1 CFA-induced inflammatory pain behaviors. Intra-
plantar injection of complete Freund’s adjuvant (CFA) caused
significant reduction in PWTL (from 12.7160.80 to 6.8961.11 s,
n=6, p,0.05) and PWMT (from 117.6067.16 to
42.4769.35 mN, n=6, p,0.001), suggesting the establishment
of CFA-induced inflammatory heat (A) and mechanical (B) pain
hypersensitivity.
(TIF)
Figure S2 Comparison of mRNA expressions of a-subunit of
voltage-gated sodium channels in DRG and spinal cord. A, By
RT-PCR analysis, mRNA encoding NaV1.1, NaV1.6, NaV1.7,
NaV1.8 and NaV1.9 were expressed in DRG. B, mRNA encoding
NaV1.1, NaV1.2, NaV1.6 and NaV1.7 were shown in spinal cord.
It should be noted that mRNA encoding NaV1.8 and NaV1.9 were
undetectable in spinal cord of adult rat.
(TIF)
Table S1 Primers for RT-PCR experiments. Nucleotide se-
quence of PCR primers was listed with reference to corresponding
GenBank accession numbers. For each primer pair, forward and
reverse primers were located in different exons to avoid the
amplification of genomic DNA.
(DOC)
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